Antibacterial and osteogenic activities of clindamycin-releasing mesoporous silica/carboxymethyl chitosan composite hydrogels. Issue 9 (15th September 2021)

• Record Type: Journal Article
• Authors: Sungkhaphan, Piyarat; Thavornyutikarn, Boonlom; Kaewkong, Pakkanun; Pongkittiphan, Veerachai; Pornsuwan, Soraya; Singhatanadgit, Weerachai; Janvikul, Wanida
• Is Part Of: Royal Society open science. Volume 8:Issue 9(2021)
• Publication Date: 2021-09-15
• Subjects: carboxymethyl chitosan -- MCM-41 -- clindamycin -- composite hydrogels -- antibacterial activity -- osteogenic activity; Science -- Periodicals; 500
• DOI: 10.1098/rsos.210808
• Languages: English
• ISSNs: 2054-5703

Abstract

Abstract : Conventional treatment of jaw bone infection is often ineffective at controlling bacterial infection and enhancing bone regeneration. Biodegradable composite hydrogels comprised of carboxymethyl chitosan (CMCS) and clindamycin (CDM)-loaded mesoporous silica nanoparticles (MCM-41), possessing dual antibacterial activity and osteogenic potency, were developed in the present study. CDM was successfully loaded into both untreated and plasma-treated MCM-41 nanoparticles, denoted as (p)-MCM-41, followed by the incorporation of each of CDM-loaded (p)-MCM-41 into CMCS. The resulting CDM-loaded composite hydrogels, (p)-MCM-41-CDM-CMCS, demonstrated slow degradation rates (about 70% remaining weight after 14-day immersion), while the CDM-free composite hydrogel entirely disintegrated after 4-day immersion. The plasma treatment was found to improve drug loading capacity and slow down initial drug burst effect. The prolonged releases of CDM from both (p)-MCM-41-CDM-CMCS retained their antibacterial effect against Streptococcus sanguinis for at least 14 days in vitro. In vitro assessment of osteogenic activity showed that the CDM-incorporated composite hydrogel was cytocompatible to human mesenchymal stem cells (hMSCs) and induced hMSC mineralization via p38-dependent upregulated alkaline phosphatase activity. In conclusion, novel (p)-MCM-41-CDM-CMCS hydrogels with combined controlled release of CDM and osteogenic potency were successfully developed for the first time, suggesting their potential clinical benefit for treatment of intraoral bone infection.